Basem A Dahshan1, Joshua S Weir1, Robert P Bice1, Paul Renz2, Daniel T Cifarelli3, Linda Poplawski1, Joshua Hack1, John A Vargo4, Christopher P Cifarelli5. 1. Department of Radiation Oncology, West Virginia University, Morgantown, WV. 2. Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA. 3. Department of Neurosurgery, West Virginia University, Morgantown, WV. 4. Department of Radiation Oncology, UPMC, Pittsburgh, PA. 5. Department of Radiation Oncology, West Virginia University, Morgantown, WV; Department of Neurosurgery, West Virginia University, Morgantown, WV. Electronic address: cpcifarelli@hsc.wvu.edu.
Abstract
PURPOSE: Although surgery remains a treatment option for symptomatic brain metastases, the need for adjuvant radiation after surgery is widely accepted as standard. Despite a multitude of randomized trials aimed at identifying the ideal radiation treatment plan for surgically resected metastases, the development of new delivery regiments necessitates a periodic re-evaluation of dosimetric performance/outcome. Here, we compare the homogeneity index (HI) across three platforms: single-session stereotactic radiosurgery (SRS), multisession stereotactic radiotherapy, and intraoperative radiotherapy (IORT). METHODS AND MATERIALS: Patients treated with IORT after surgical resection of brain metastases were identified and dosimetric parameters collected from the dose-volume histograms based on the development of conformal plans for adjuvant radiation using Gamma Knife-SRS (GK-SRS), linear accelerator based intensity-modulated radiation therapy, and IORT. HIs were calculated using four established methods and compared across platforms within the patient cohort. Statistical analyses were performed using analysis of variance. RESULTS: The mean maximal doses for the GK-SRS and IMRT plans were 30 Gy and 29 Gy with margin prescription doses of 16 Gy and 24 Gy, respectively. The IORT dose was 30 Gy to the applicator surface. HIs varied based on calculation methods, but maintained consistency when comparing across platforms with IORT having the lower mean HI value (0.56; 95% confidence interval (CI) 0.55-0.60) in single-fraction treatment, compared with GK-SRS (0.77; 95% CI 0.76-0.80). The mean multisession IMRT HI was lower than both single-fraction treatment modalities at 0.41 (95% CI 0.40-0.42). CONCLUSIONS: When using the HI as the primary dosimetric parameter for adjuvant radiation plans after surgical resection of brain metastases IORT offers improved dose homogeneity compared with GK-SRS in single-fraction treatment, whereas fractionated LINAC-based IMRT was superior with respect to the HI in comparison among all three methods.
PURPOSE: Although surgery remains a treatment option for symptomatic brain metastases, the need for adjuvant radiation after surgery is widely accepted as standard. Despite a multitude of randomized trials aimed at identifying the ideal radiation treatment plan for surgically resected metastases, the development of new delivery regiments necessitates a periodic re-evaluation of dosimetric performance/outcome. Here, we compare the homogeneity index (HI) across three platforms: single-session stereotactic radiosurgery (SRS), multisession stereotactic radiotherapy, and intraoperative radiotherapy (IORT). METHODS AND MATERIALS: Patients treated with IORT after surgical resection of brain metastases were identified and dosimetric parameters collected from the dose-volume histograms based on the development of conformal plans for adjuvant radiation using Gamma Knife-SRS (GK-SRS), linear accelerator based intensity-modulated radiation therapy, and IORT. HIs were calculated using four established methods and compared across platforms within the patient cohort. Statistical analyses were performed using analysis of variance. RESULTS: The mean maximal doses for the GK-SRS and IMRT plans were 30 Gy and 29 Gy with margin prescription doses of 16 Gy and 24 Gy, respectively. The IORT dose was 30 Gy to the applicator surface. HIs varied based on calculation methods, but maintained consistency when comparing across platforms with IORT having the lower mean HI value (0.56; 95% confidence interval (CI) 0.55-0.60) in single-fraction treatment, compared with GK-SRS (0.77; 95% CI 0.76-0.80). The mean multisession IMRT HI was lower than both single-fraction treatment modalities at 0.41 (95% CI 0.40-0.42). CONCLUSIONS: When using the HI as the primary dosimetric parameter for adjuvant radiation plans after surgical resection of brain metastases IORT offers improved dose homogeneity compared with GK-SRS in single-fraction treatment, whereas fractionated LINAC-based IMRT was superior with respect to the HI in comparison among all three methods.
Authors: Brigitta G Baumert; Isabelle Rutten; Cary Dehing-Oberije; Albert Twijnstra; Miranda J M Dirx; Ria M T L Debougnoux-Huppertz; Philippe Lambin; Bela Kubat Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-11 Impact factor: 7.038
Authors: Bree R Eaton; Michael J LaRiviere; Michael J La Riviere; Sungjin Kim; Roshan S Prabhu; Kirtesh Patel; Shravan Kandula; Nelson Oyesiku; Jeffrey Olson; Walter Curran; Hui-Kuo Shu; Ian Crocker Journal: J Neurooncol Date: 2015-04-11 Impact factor: 4.130
Authors: Peng Dong; Angélica Pérez-Andújar; Dilini Pinnaduwage; Steve Braunstein; Philip Theodosopoulos; Michael McDermott; Penny Sneed; Lijun Ma Journal: J Neurosurg Date: 2016-12 Impact factor: 5.115
Authors: E Shaw; C Scott; L Souhami; R Dinapoli; R Kline; J Loeffler; N Farnan Journal: Int J Radiat Oncol Biol Phys Date: 2000-05-01 Impact factor: 7.038
Authors: Christopher P Cifarelli; Stefanie Brehmer; John Austin Vargo; Joshua D Hack; Klaus Henning Kahl; Gustavo Sarria-Vargas; Frank A Giordano Journal: J Neurooncol Date: 2019-10-25 Impact factor: 4.130
Authors: Adrian Nalichowski; Isaac Kaufman; John Gallo; Todd Bossenberger; Tim Solberg; Ezequiel Ramirez; Yulong Yan; Julie Fredrick; Tewfik Bichay; Alan Mayville; Jay Burmeister Journal: J Appl Clin Med Phys Date: 2016-12-29 Impact factor: 2.102
Authors: Anita Mahajan; Salmaan Ahmed; Mary Frances McAleer; Jeffrey S Weinberg; Jing Li; Paul Brown; Stephen Settle; Sujit S Prabhu; Frederick F Lang; Nicholas Levine; Susan McGovern; Erik Sulman; Ian E McCutcheon; Syed Azeem; Daniel Cahill; Claudio Tatsui; Amy B Heimberger; Sherise Ferguson; Amol Ghia; Franco Demonte; Shaan Raza; Nandita Guha-Thakurta; James Yang; Raymond Sawaya; Kenneth R Hess; Ganesh Rao Journal: Lancet Oncol Date: 2017-07-04 Impact factor: 41.316